Effectiveness and safety of certolizumab pegol in rheumatoid arthritis patients in Canadian practice: 2-year results from the observational FαsT-CAN study.

21 However, the REALISTIC study showed similar improvements in DAS28(CRP) and ACR20, 50 and 70 responses when patients were stratified by prior anti-TNF use; although a numerical trend for higher response rates was observed in anti-TNF-naïve patients. 22 Similarly, the results from the South Swedish Arthritis Treatment Group Register showed that first-time anti-TNF switchers had similar response rates to anti-TNF-naïve patients. 23 Patient-reported outcomes showed CZP treatment improved symptoms such as fatigue and arthritis associated pain through Week 104.

also in 1,012 other papers